- Home
- NGNE
NGNE
Neurogene Inc.
as 12-20-2024 4:00pm EST
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 352.4M | IPO Year: | N/A |
| Target Price: | $60.80 | AVG Volume (30 days): | 481.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.41 - $74.49 | Next Earning Date: | 11-18-2024 |
| Revenue: | $925,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Neurogene Inc. (NGNE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Samsara BioCapital GP, LLC | NGNE | 10% Owner | Nov 26 '24 | Buy | $26.29 | 48,770 | $1,259,622.58 | 1,689,105 | |
| McMinn Rachel | NGNE | Chief Executive Officer | Nov 22 '24 | Buy | $20.40 | 47,500 | $969,000.00 | 1,297,859 | |
| Cvijic Christine Mikail | NGNE | President and CFO | Nov 22 '24 | Buy | $20.48 | 24,000 | $491,400.00 | 76,844 |
Latest Neurogene Inc. News
NGNE Breaking Stock News: Dive into NGNE Ticker-Specific Updates for Smart Investing
Argus Research
25 days ago
Daily – Vickers Top Buyers & Sellers for 11/27/2024
Business Wire
a month ago
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
Investor's Business Daily
a month ago
How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week
Business Wire
a month ago
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Investor's Business Daily
a month ago
Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal
GuruFocus.com
a month ago
Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Data
Business Wire
a month ago
Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
TipRanks
2 months ago
Neurogene Secures $200M for Genetic Therapy Development
Compare NGNE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NGNE Neurogene Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.